Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 2,461–2,520 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…nts recieved corticosteroids, and 48.7% recieved antimalarials. Mycophenolate mofetil, rituximab and cyclophosphamide were the most commonly used imm…
…lation with the skin score(r=-0.271) and with the total dose of rituximab(r=-0.38) was established.There was no correlation between the i…
…i-Scl70 in 70%, anticentromere in 13%, and rarer specificities (RNAP III, fibrillarin, PM/Scl) in 3% each. Regarding objective 1, there …
…st recent clinic letter) were reflux (32%) and dysphagia (28%). Proton pump inhibitor (PPI) use was high (81%).Both anticentromere (n=57) and anti-Sc…
…oratory-based (morning) temperatures) may be due to the time of sildenafil dosing and/or a greater number of home-based (daily) measures f…
… loss and worsening inflammatory arthralgias despite successive methotrexate dose escalations. Cardiopulmonary assessment revealed nonspecif…
…ial lung disease (68%). The top first-line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%) and hydroxychloroquine (20%).Conclusi…
… exchange (TPE), cyclophosphamide, and maintenance therapy with mycophenolate mofetil or rituximab in cases of intolerance. Samples were obtained at …
…se duration, SSc subtype, and ILD, indicated that a doubling of PRO-C7 at baseline were associated to FVC worsening with a hazard rati…
…ne autoleucel (relma-cel) in progressive diffuse cutaneous SSc. Relma-cel demonstrated a favorable safety profile across six patients. Al…
…All patients received cyclophosphamide and/or advanced therapy (Rituximab/Tocilizumab) before transplantation; three of them did not requ…
… treated with glucocorticoids, and one patient was treated with tocilizumab and eculizumab. A DLCO <60% of predicted was significantly asso…